Truist Financial Sticks to Their Hold Rating for AvalonBay (AVB)
Truist Financial analyst Michael Lewis maintained a Hold rating on AvalonBay (AVB – Research Report) today and set a price target of $230.00.
Avobis Bio Receives FDA Fast Track Designation for AVB-114 Implantable Cell Therapy for Crohn's Perianal Fistulas
Avobis Bio LLC, a clinical stage company developing implantable cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AVB-114, the ...
Yahoo Finance24d
AvalonBay Communities, Inc. (AVB)
ARLINGTON, Va., February 05, 2025--AvalonBay Communities, Inc. (NYSE: AVB) (the "Company") reported Earnings per Share – diluted ("EPS"), Funds from Operations ...